Maravai LifeSciences Reports Officer/Director Changes

Ticker: MRVI · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1823239

Maravai Lifesciences Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyMaravai Lifesciences Holdings, Inc. (MRVI)
Form Type8-K
Filed DateOct 27, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, officer-appointment, director-election, compensation

Related Tickers: MRVI

TL;DR

Maravai LifeSciences (MRVI) just filed an 8-K detailing leadership shakeups and new pay structures.

AI Summary

Maravai LifeSciences Holdings, Inc. filed an 8-K on October 27, 2025, reporting changes effective October 21, 2025. The filing indicates a departure of directors or certain officers, the election of new directors, and the appointment of certain officers, along with updates to compensatory arrangements for these officers.

Why It Matters

Changes in key leadership and officer compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in executive and director roles, especially when accompanied by compensation adjustments, can introduce uncertainty about future strategy and operational direction.

Key Players & Entities

  • Maravai LifeSciences Holdings, Inc. (company) — Registrant
  • October 21, 2025 (date) — Effective date of reported events
  • October 27, 2025 (date) — Filing date of the 8-K

FAQ

Who specifically departed from Maravai LifeSciences' board or officer positions?

The filing indicates a departure of directors or certain officers, but does not name the specific individuals in this summary.

Were any new directors elected to the Maravai LifeSciences board?

Yes, the filing explicitly states the election of directors as an item being reported.

What specific officer positions were filled or changed?

The filing mentions the appointment of certain officers, but does not detail the specific roles affected.

Are there details on the new compensatory arrangements for the appointed officers?

The filing notes that compensatory arrangements of certain officers are being updated, but specific details are not provided in this summary.

What is the effective date for these reported changes at Maravai LifeSciences?

The earliest event reported is dated October 21, 2025.

Filing Stats: 608 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-10-27 16:23:34

Key Financial Figures

  • $0.01 — which registered Class A Common Stock, $0.01 par value MRVI The Nasdaq Stock Market

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MARAVAI LIFESCIENCES HOLDINGS, INC. Date: October 27, 2025 By: /s/ Rajesh Asarpota Name: Rajesh Asarpota Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.